1 hot UK growth stock I’m buying right now

I’ve more than doubled my money on this UK growth stock. But with a 948% boost to earnings, I think Hvivo is an even better buy now.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Businessman use electronic pen writing rising colorful graph from 2023 to 2024 year of business planning and stock investment growth concept.

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

It’s not often I put thousands of pounds into one UK growth stock. But my research has led me to handpick this one opportunity, and I’m buying more.

With an expected 948% increase in earnings in the next 12 months, I think Hvivo (LSE:HVO) could be a winner for me.

Hvivo shares shot up to a peak of 38p amid the global investor frenzy around Covid stocks. Today the shares are worth half that, at around 20p. So why am I adding to my position?

I first noticed Hvivo during the pandemic when its market cap was a tiny £30m. Today the company is worth around £135m.

It runs human challenge clinical trials for flu and other respiratory illnesses. its scientists expose healthy volunteers to infection under strict quarantine standards. They’re then given potential treatment medicines from major biopharma companies, including Pfizer.

The studies are incredibly valuable for Hvivo’s clients because they create cost-effective data much faster than other testing methods.

Rapid growth

Poorly-understood illnesses like long Covid and other respiratory viruses loom large over the global population.

And since 2020 the number of pharma companies testing vaccines and antivirals has soared. This is creating booming demand for Hvivo’s services.

Analysts see its bottom line improving from a £770,000 net loss in 2022 to a £7.54m profit in 2023. That’s the predicted 948% earnings increase I mentioned earlier. The company has also this year increased its profit margins from under 13% to 19%, and upped its revenue guidance.

Adding to this year’s record £78m order book is a £6.8m contract signed in February, followed by a £13.1m contract win in July.

Results released in September showed profit for the first half of the year up 126% to £5.2m. Net cash has also doubled to £31.3m (around 4.6p per share) in the last 12 months. Analysts have upgraded their earnings estimates for the next two years by 62% and 46%, respectively.

Risk and rewards

A quick word on risks though. Hvivo is listed on the UK’s AIM market. AIM shares are generally less liquid — that is, there are fewer buyers and sellers — than companies on the FTSE 100 or FTSE 250.

The other main risk (as with all growth stocks) is that expectations might not meet reality. That 948% increase could fall short, for instance, putting off new investors. For me, this is a calculated risk. I’ve taken into account what I think is a realistic assessment of the company’s mis-steps and successes to date.

Additionally, testing infectious and respiratory diseases on human volunteers remains a controversial practice.

Yet in my opinion, the risk is mitigated by Hvivo’s track record in running successful studies, along with having on-site immunology and virology laboratories.

Pharma karma

Hvivo is a picks and shovels play for my investment portfolio. Instead of bottomless R&D spending on creating vaccines or treatments? Hvivo only helps to test those medicines, and is paid handsomely for doing so.

Back in 2020, I wrote for The Motley Fool that I thought Hvivo shares could double my money.

They have — and more.

And with these analyst upgrades, I see even better growth ahead. So I’m doubling down again on Hvivo.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Tom Rodgers has positions in Hvivo Plc. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
Investing Articles

2 high-yield FTSE 250 shares I’d buy today — and 1 that I’d avoid

UK markets have felt some volatility after last week’s Budget and the FTSE 250 was no stranger to it. Our…

Read more »

Investing Articles

3 reasons the Rolls-Royce share price could soar over the next decade

Sustainable aviation fuel, narrow-body aircraft, and small nuclear reactors could all keep the Rolls-Royce share price climbing over the next…

Read more »

British flag, Big Ben, Houses of Parliament and British flag composition
Investing Articles

Here’s how much income I’d get if I invested my entire £20k ISA in cheap BT shares

BT shares are on the up but still cheap, while the FTSE 100 telecoms stock offers a good yield too.…

Read more »

Investing Articles

2 FTSE dividend shares yielding more than 6% with P/Es of less than 9!

Harvey Jones picks out two brilliant FTSE 100 dividend shares that yield more than 6% but are selling at strangely…

Read more »

Investing Articles

Up 105% in a year! Is this rocketing FTSE bank the perfect pick for my Stocks and Shares ISA?

Harvey Jones is drawing up a shortlist of stocks to purchase inside his Stocks and Shares ISA allowance. This FTSE…

Read more »

Investing Articles

Down 78%, is this once-hot AI growth stock set to explode like the Rolls-Royce share price?

Our writer asks if he should invest in Super Micro Computer (NASDAQ:SMCI) following the growth stock's massive recent decline.

Read more »

Investing Articles

Is it madness to buy Palantir shares after Q3 earnings?

Palantir stock's surging again after the firm's Q3 earnings report. But after a 150% gain, is it too late to…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

£6,000 in savings? Here’s how I’d aim to turn that into £1,032 a month of passive income!

A small investment in high-dividend-paying stocks with the returns used to buy more shares can generate big passive income over…

Read more »